MetaCap

Grifols S.A. (GRFS) vs Mirum Pharmaceuticals (MIRM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mirum Pharmaceuticals (MIRM) has outperformed Grifols S.A. (GRFS) over the past year, gaining 35.5% versus a loss of 3.0%. Over five years, MIRM leads with a +616.9% price change compared with -25.3% for GRFS. Mirum Pharmaceuticals is the larger company by market cap ($6.28 billion vs $5.55 billion), about 1.1 times the size.

On valuation, Grifols S.A. trades at a lower forward P/E (6.6x vs 300.4x for Mirum Pharmaceuticals).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRFS-2.98%MIRM+35.45%
+86%+32%-21%
Nov 21, 20251 yearNov 20, 2026
GRFS-31.40%MIRM+512.68%
+738%+326%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRFS versus MIRM key metrics
MetricGRFSMIRM
Share price$8.15$96.13
Market cap$5.55B$6.28B
1-day change-0.61%+0.65%
YTD return-12.83%+21.70%
1-year return-2.98%+35.45%
5-year return-25.30%+616.85%
P/E ratio (TTM)9.82—
Forward P/E6.55300.41
EPS (TTM)$0.83$-14.47
Dividend yield1.30%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$521.31M
Revenue growth (YoY)—+54.74%
Net income (latest FY)—$-23.36M
Operating margin—-4.25%
Net margin—-4.48%
52-week high$9.77$130.00
52-week low$6.96$63.23
Distance from 52-week high-16.58%-26.05%
Analyst consensusbuystrong_buy
Avg. price target upside+27.24%+64.06%
Average volume628.64K692.51K
Shares outstanding258.22M65.28M
Employees25,000470
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRM has outperformed GRFS by 38.4 percentage points over the past year.
  • Grifols S.A. offers a meaningfully higher dividend yield (1.30% vs 0.00%).

About Grifols S.A.

GRFS stock →

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Health Care · Biotechnology: Pharmaceutical Preparations · 25,000 employees

About Mirum Pharmaceuticals

MIRM stock →

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees

GRFS vs MIRM FAQ

Which is bigger, Grifols S.A. or Mirum Pharmaceuticals?

Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $6.28B compared with $5.55B for Grifols S.A. (GRFS).

Which stock has performed better over the past year, GRFS or MIRM?

MIRM returned +35.45% over the past 12 months, compared with -2.98% for GRFS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Grifols S.A. or Mirum Pharmaceuticals?

Grifols S.A. pays a dividend yielding 1.30%, while Mirum Pharmaceuticals does not currently pay a regular dividend.

Are Grifols S.A. and Mirum Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons